Derek J. Maetzold, serving as President and Chief Executive Officer of Castle Biosciences Inc. (NASDAQ:CSTL), executed a series of transactions involving the company's common stock on June 15, 2026. The executive sold a total of 4,172 shares for approximately $86,193. These sales were executed at prices ranging from $20.44 to $20.98 per share, resulting in a weighted-average sale price of $20.66. On the same date, Maetzold also acquired 550 shares of common stock through the exercise of stock options for $1,314. The exercise price for these options was $2.39 per share. All reported transactions were conducted pursuant to a Rule 10b5-1 plan adopted on December 3, 2025.
The structure of the sales involved both direct holdings and indirect ownership through various trusts. The 550 shares sold directly were held by Mr. Maetzold. Indirect sales were reported from multiple trusts: 1,357 shares from The Maetzold Descendants 2020 Trust, 1,153 shares from the Derek Maetzold 2020 Irrevocable Trust, and a total of 1,112 shares distributed across four separate Maetzold 2018 Remainder Trusts. These trusts were established for Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, and Peter Douglas Maetzold. Mr. Maetzold serves as the trustee for the Derek Maetzold 2020 Irrevocable Trust and the four 2018 Remainder Trusts. His spouse acts as the trustee for The Maetzold Descendants 2020 Trust.
Following these transactions, Mr. Maetzold's direct holdings consist of 21,479 shares of common stock. His indirect holdings are substantial, including shares held by the previously mentioned trusts. Additional indirect shares are held by DJM Grantor Retained Annuity Trust No. 6, which contains 18,718 shares, DJM Grantor Retained Annuity Trust No. 7 with 44,323 shares, and DJM Grantor Retained Annuity Trust No. 8 with 40,935 shares. The acquisition of the 550 shares resulted from the exercise of fully vested stock options.
These insider transactions occur as Castle Biosciences stock trades at $20.25, reflecting a decline of nearly 49% over the past six months. According to InvestingPro analysis, the stock appears undervalued at current levels, with shares trading below the platform's calculated Fair Value. The company maintains a market capitalization of $621 million and boasts a strong gross profit margin of 78%. For deeper insights into Castle Biosciences' financial health and growth prospects, InvestingPro offers access to over 8 additional exclusive ProTips, comprehensive Pro Research Reports covering 1,400+ US equities, and detailed valuation metrics.
In other recent developments, Castle Biosciences reported first-quarter 2026 earnings with significant revenue growth. The company posted revenue of $83.7 million, which surpassed the forecasted $77.46 million. The company's earnings per share were in line with expectations, recording a loss of $0.49. Additionally, Castle Biosciences announced that its TissueCypher Barrett’s Esophagus Test has exceeded 100,000 clinical test orders. This test is designed to predict the risk of progression from Barrett’s esophagus to more severe conditions.
Meanwhile, BTIG adjusted its price target for Castle Biosciences from $50 to $40, although it maintained a Buy rating. This adjustment was due to increased operating expense estimates as the company invests in sales, marketing, and new product development. These developments underscore the company's ongoing efforts to expand its market presence and product offerings. The stock closed at $20.25 on the reported date, with after-hours trading showing minimal movement.